Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has begun shipping Ketotifen Fumarate ophthalmic solution, 0.025%, a generic version of Zaditor™.
Zaditor™ is a sterile ophthalmic solution containing ketotifen for topical administration to the eyes and is indicated for the temporary prevention of itching of the eye due to allergic conjunctivitis. Estimated annual brand sales for the product during the last twelve months were $15 million, according to Wolters Kluwer data.
Perrigo's Chairman and CEO Joseph C. Papa stated, "Perrigo is excited to launch into a new adjacent OTC category, ophthalmics. This product is another example of Perrigo's commitment to expand our portfolio and bring new products to market. It further demonstrates our strategy to deliver quality affordable healthcare products."